0001209191-20-043544.txt : 20200723
0001209191-20-043544.hdr.sgml : 20200723
20200723185029
ACCESSION NUMBER: 0001209191-20-043544
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200723
FILED AS OF DATE: 20200723
DATE AS OF CHANGE: 20200723
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tong Jeffrey K
CENTRAL INDEX KEY: 0001479701
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39398
FILM NUMBER: 201044707
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nurix Therapeutics, Inc.
CENTRAL INDEX KEY: 0001549595
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270838048
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: (415) 660-5320
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: Nurix, Inc.
DATE OF NAME CHANGE: 20120509
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-07-23
0
0001549595
Nurix Therapeutics, Inc.
NRIX
0001479701
Tong Jeffrey K
C/O NURIX THERAPEUTICS, INC.
1700 OWENS STREET, SUITE 205
SAN FRANCISCO
CA
94158
1
0
1
0
Director Stock Option (right to buy)
9.57
2030-05-27
Common Stock
18333
D
Series A-2 Preferred Stock
0.00
Common Stock
0
I
See footnote
Series B Preferred Stock
0.00
Common Stock
0
I
See footnote
Series D Preferred Stock
0.00
Common Stock
0
I
See footnote
The stock option vests as to 1/48 of the total shares monthly beginning May 28, 2020 until the option is fully vested on April 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
Third Rock Ventures III, L.P. (the "Fund") holds 875,000, 4,508,333, and 39,215 shares of Series A-2, Series B and Series D Preferred Stock of the Issuer. The reporting person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of the Fund. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
/s/ Christine Ring, as Attorney-in-Fact for Jeffrey Tong
2020-07-23
EX-24.3_930013
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY
The undersigned hereby constitutes and appoints Christine Ring and Hans van
Houte, as long as they are providing services to Nurix Therapeutics, Inc. or its
related entities (the "Company"), or either of them, the undersigned's true and
lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of the Company, Forms 3, 4 and 5 in accordance
with Section 16(a) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and the rules and regulations thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute any such Forms 3, 4 and 5
and timely file such forms with the Securities and Exchange Commission and any
stock exchange or similar authority, if required; and
(3) take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform each and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution and revocation,
hereby ratifying and confirming all that each such attorney-in-fact, or each
such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to
be done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
The undersigned agrees that each such attorney-in-fact may rely entirely on
information furnished orally or in writing by the undersigned to each such
attorney-in-fact. The undersigned also agrees to indemnify and hold harmless
the Company and each such attorney-in-fact against any losses, claims, damages
or liabilities (or actions in these respects) that arise out of or are based on
any untrue statement or omission of necessary facts in the information provided
by the undersigned to such attorney-in-fact for purposes of executing,
acknowledging, delivering and filing Forms 3, 4 or 5 (including amendments
thereto) and agrees to reimburse the Company and each such attorney-in-fact for
any legal or other expenses reasonably incurred in connection with investigating
or defending against any such loss, claim, damage, liability or action.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 29th day of June, 2020.
/s/ Jeffrey Tong
Name: Jeffrey Tong